http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-103925-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2016-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-103925-A1 |
| titleOfInvention | TREATMENT COMBINED WITH A TLR7 AGONIST AND AN INHIBITOR OF THE HBV CAPSID ASSEMBLY |
| abstract | Compositions and methods for treating hepatitis B virus infection. Combination therapy comprising the administration of a TLR7 agonist and an inhibitor of HBV capsid assembly for use in the treatment of a chronic hepatitis B patient. . Claim 2: The pharmaceutical composition according to claim 1, wherein the TLR7 agonist is a compound of formula (1), wherein R¹ is hydroxy, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkylcarbonyl -O-, C₁₋₆-S- alkyl, azido, cyano, C₂₋₆ alkenyl, C₁₋₆-NH- alkylsulfonyl, (C₁₋₆ alkyl) N-, C,-NH- alkylcarbonyl or heterocyclic amino; R² is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, benzyl and thiophenyl; R³ is hydrogen or C₁₋₆carbonyl alkyl; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Claim 4: The pharmaceutical composition according to claim 1, wherein the TLR7 agonist is a compound of formula (2), wherein R⁴ and R⁵ are independently selected from hydrogen, C₂₋₆ alkenyl and C₁₋₆ alkyl ; R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and 2-thiophenyl; R⁸ is hydrogen or C₁₋₆carbonyl alkyl; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Claim 7: The pharmaceutical composition according to claim 1, wherein the HBV capsid assembly inhibitor is a compound of formula (3), wherein R⁹ is C₁₋₆ alkyl; R¹⁰ is phenyl, which is substituted once or twice or three times with halogen or C₁₋₆ alkyl; R¹¹ is hydrogen or C₁₋₆ alkyl; R² is monocyclic heterocyclyl, bicyclic condensate or bicyclic bridging; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof. Claim 13: The pharmaceutical composition according to any one of claims 1 to 12, wherein said other antiviral agents are selected from lamivudine, adefovir, tenofovir, telbivudine and entecavir. Claim 14: A method for the manufacture of a medicament for the treatment or prophylaxis of hepatitis B virus infection, characterized in that a TLR7 agonist and an inhibitor of HBV capsid assembly in the medicament are used. Claim 36: The use of the pharmaceutical composition according to claims 1 to 13 in the form of an antiviral medicament, in particular as the medicament for the treatment or prophylaxis of hepatitis B virus infection. Claim 37: The use of a TLR7 agonist and a HBV capsid assembly inhibitor for the manufacture of a pharmaceutical composition according to claims 1 to 13 in the form of an antiviral drug, in particular the drug for the treatment or prophylaxis of the infection for the hepatitis B virus. |
| priorityDate | 2015-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 30.